PRECIGEN, INC.
Precigen, Inc. (Nasdaq: PRGN) is a commercial-stage biopharmaceutical company specializing in precision medicines targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company's website is www.precigen.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PRECIGEN, INC. does
In the company’s own words
Precigen, Inc. (Nasdaq: PRGN) is a commercial-stage biopharmaceutical company specializing in precision medicines targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company's website is www.precigen.com.
Precigen achieved a significant milestone in August 2025 when the FDA granted full approval to Papzimeos (zopapogene imadenovec-drba), marking the first and only FDA-approved therapy for treating adults with recurrent respiratory papillomatosis, a rare, debilitating disease caused by chronic human papillomavirus infection. The company has launched Papzimeos in the United States with commercial infrastructure in place, including partnerships with leading commercialization service providers and secured coverage from private health plans covering approximately 215 million lives, along with Medicare and Medicaid coverage.
The company's therapeutic pipeline includes PRGN-2009, based on its AdenoVerse immunotherapy platform for HPV-associated cancers, and multiple UltraCAR-T candidates including PRGN-3006, which has completed enrollment in Phase 1b trials for relapsed or refractory acute myeloid leukemia. The company has strategically paused enrollment in certain CAR-T programs to prioritize resources toward the most promising candidates.
Precigen's competitive advantages center on proprietary technology platforms including AdenoVerse, featuring gorilla adenovectors with large genetic payload capacity and suitability for repeat administration, and UltraCAR-T, utilizing non-viral manufacturing enabling overnight decentralized production. The company has developed the UltraPorator, a proprietary electroporation device cleared by the FDA for manufacturing clinical trial therapies. Additionally, Precigen operates internal cGMP manufacturing capabilities in Germantown, Maryland, for AdenoVerse-based therapeutics, reducing reliance on contract manufacturers.
The company operates under core tenets of financial discipline, active portfolio management, rapid execution, and strategic partnerships. Precigen estimates approximately 27,000 adult RRP patients in the United States represent the addressable market for Papzimeos. The company continues advancing its clinical programs toward proof-of-concept and commercialization, either independently or through collaborations, including a cooperative research and development agreement with the National Cancer Institute for PRGN-2009 development.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- GERMANTOWN, MD
- Fiscal year end
- December
- CIK
- 1356090
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PRECIGEN, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PRECIGEN, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PRECIGEN, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PRECIGEN, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PRECIGEN, INC.'s last four quarterly filings that the numbers alone won't show?”